Efficacy and safety analysis of anlotinib combined with etoposide plus cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (SCLC): The final results from a phase II single-arm trial.

被引：4
|
作者：
Kong, Tiandong [1 ]
Chen, Lu [1 ]
Duan, Fangfang [1 ]
Hou, Xiaoxia [1 ]
Wang, Liuyan [1 ]
Zhou, Hanli [1 ]
Wang, Lanrong [1 ]
Hu, Shanshan [1 ]
Liu, Danna [1 ]
机构：
[1] Henan Univ, Peoples Hosp Zhengzhou City 3, Canc Hosp, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.8560
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8560
引用
下载
收藏
页数：3
相关论文
共 50 条
  • [31] Phase Ib study of CC-90011 plus etoposide and cisplatin (EP) in patients with first-line extensive-stage (ES) small cell lung cancer (SCLC)
    Paz-Ares, L.
    Juan-Vidal, O.
    Carcereny, E.
    Greillier, L.
    Navarro, A.
    Bennouna, J.
    Santoro, A.
    Berardi, R.
    Besse, B.
    Salvagni, S.
    Gonzalez, H.
    de Alvaro, J.
    Parra-Palau, J.
    Sanchez-Perez, T.
    Aronchik, I.
    Filvaroff, E.
    Lamba, M.
    Nikolova, Z.
    Ponce, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S482 - S483
  • [32] Updated safety and efficacy results of SHR-1316 combined with chemotherapy and sequential chest radiotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) from a phase II trial
    Chen, Dawei
    Gao, Aiqin
    Huang, Wei
    Shao, Qian
    Meng, Xiangjiao
    Tang, Xiaoyong
    Zhang, Pinliang
    Hu, Xudong
    Zhang, Yan
    Guo, Jun
    Fu, Lei
    Zhao, Wei
    Zhao, Changhong
    Yuan, Jiajia
    Yu, Jinming
    Wang, Linlin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] Phase II Study of Celecoxib with Cisplatin Plus Etoposide in Extensive-Stage Small Cell Lung Cancer
    Araujo, Antonio M. F.
    Mendez, Jose C.
    Coelho, Ana L.
    Sousa, Berta
    Barata, Fernando
    Figueiredo, Ana
    Amaro, Teresina
    Azevedo, Isabel
    Soares, Marta
    CANCER INVESTIGATION, 2009, 27 (04) : 391 - 396
  • [34] Phase II study of Celecoxib with Cisplatin plus Etoposide in extensive-stage small cell lung cancer
    Araujo, Antonio M. F.
    Mendez, J. Carlos
    Sousa, Berta A.
    Barata, Fernando
    Figueiredo, Ana
    Azevedo, Isabel M.
    Amaro, Teresina
    Sousa, Maria J.
    Costa, Carla
    Lopes, J. MaChado
    ANNALS OF ONCOLOGY, 2004, 15 : 191 - 191
  • [35] Phase II study of celecoxib with cisplatin plus etoposide in extensive-stage small cell lung cancer
    Araujo, Antonio M. F.
    Mendez, Jose C.
    Sousa, Berta
    Barata, Fernando
    Figueiredo, Ana
    Amaro, Teresina
    Coelho, Ana
    Azevedo, Isabel
    Soares, Marta
    ANNALS OF ONCOLOGY, 2006, 17 : 232 - 232
  • [36] Preliminary safety and efficacy of camrelizumab plus nab-paclitaxel and carboplatin as frontline setting in extensive-stage small cell lung cancer (ES-SCLC) from a phase II trial.
    Ren, Shengxiang
    Yu, Jia
    Xiong, Anwen
    Wang, Qi
    Wang, Lei
    Chen, Bin
    Yang, Menghang
    Li, Wei
    Yuan, Jiajia
    Zhao, Changhong
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] A NOVEL PHASE II TRIAL OF IPILIMUMAB, CARBOPLATIN AND ETOPOSIDE (ICE) FOR THE FIRST LINE TREATMENT OF EXTENSIVE STAGE SMALL CELL LUNG CANCER (SCLC)
    Ottensmeier, C.
    Galea, I.
    Cross, N.
    Maishman, T.
    Hamid, D.
    Cave, J.
    Wheater, M.
    Geldart, T.
    Mulatero, C.
    Potter, V.
    Danson, S.
    Woll, P.
    Griffiths, R.
    Nolan, L.
    ANNALS OF ONCOLOGY, 2014, 25
  • [38] Safety and efficacy of durvalumab plus carboplatin and etoposide for patients with previously untreated extensive-stage small-cell lung cancer (ES-SCLC) with a poor performance status: The results from phase II single-arm study (NEJ045A study).
    Saida, Yu
    Asao, Tetsuhiko
    Watanabe, Satoshi
    Kisohara, Akira
    Kishi, Kazuma
    Morita, Ryo
    Nakagawa, Taku
    Tsukita, Yoko
    Furuya, Naoki
    Miyawaki, Taichi
    Ishikawa, Nobuhisa
    Yamada, Tadaaki
    Tanaka, Takahiro
    Morita, Satoshi
    Kikuchi, Toshiaki
    Maemondo, Makoto
    Kobayashi, Kunihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Phase II study of roniciclib in combination with cisplatin/etoposide or carboplatin/etoposide as first-line therapy in subjects with extensive-disease small cell lung cancer (ED-SCLC)
    Reck, M.
    Horn, L.
    Novello, S.
    Barlesi, F.
    Albert, I.
    Juhasz, E.
    Chung, J.
    Fritsch, A.
    Drews, U.
    Rutstein, M.
    Wagner, A.
    Govindan, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [40] Anlotinib plus standard chemotherapy as first-line treatment in extensive-stage small cell lung cancer patients
    Zhang, W.
    Yang, H.
    Kong, T.
    Han, B.
    ANNALS OF ONCOLOGY, 2022, 33 : S1580 - S1580
12345